BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33688985)

  • 21. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.
    Chen F; Huhdanpaa H; Desai B; Hwang D; Cen S; Sherrod A; Bernhard JC; Desai M; Gill I; Duddalwar V
    Springerplus; 2015; 4():66. PubMed ID: 25694862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.
    Takahashi M; Kume H; Koyama K; Nakagawa T; Fujimura T; Morikawa T; Fukayama M; Homma Y; Ohtomo K; Momose T
    Clin Nucl Med; 2015 Dec; 40(12):936-40. PubMed ID: 26164183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
    Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic Contrast-Enhanced CT Characterization of Xp11.2 Translocation/TFE3 Gene Fusions versus Papillary Renal Cell Carcinomas.
    He J; Zhou K; Zhu B; Zhang G; Li X; Guo H; Gan W; Zhou Z; Liu T
    Biomed Res Int; 2015; 2015():298679. PubMed ID: 26636097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
    Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma.
    Takahashi H; Vikram R; Jimenez RE; Bolan CW; Kawashima A; Karam JA; Takahashi N
    Abdom Radiol (NY); 2021 Nov; 46(11):5250-5259. PubMed ID: 34338814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clear cell renal cell carcinoma and papillary renal cell carcinoma: differentiation of distinct histological types with multiphase CT.
    Bata P; Gyebnar J; Tarnoki DL; Tarnoki AD; Kekesi D; Szendroi A; Fejer B; Szasz AM; Nyirady P; Karlinger K; Berczi V
    Diagn Interv Radiol; 2013; 19(5):387-92. PubMed ID: 23864331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
    Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
    Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
    Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
    Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.
    Park S; Lee HY; Lee S
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of size of region-of-interest on differentiation of renal cell carcinoma and renal cysts on multi-phase CT: preliminary findings.
    Rosenkrantz AB; Matza BW; Portnoy E; Melamed J; Taneja SS; Wehrli NE
    Eur J Radiol; 2014 Feb; 83(2):239-44. PubMed ID: 24239241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early assessment with
    Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
    BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Zhang L; Zhao H; Jiang H; Zhao H; Han W; Wang M; Fu P
    Abdom Radiol (NY); 2021 Dec; 46(12):5618-5628. PubMed ID: 34455450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT-correlation with microvascular density.
    Marcon J; Graser A; Horst D; Casuscelli J; Spek A; Stief CG; Reiser MF; RĂ¼benthaler J; Buchner A; Staehler M
    Eur Radiol; 2020 Jan; 30(1):1-10. PubMed ID: 31278580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
    Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
    Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis.
    Wang W; Cao K; Jin S; Zhu X; Ding J; Peng W
    Eur Radiol; 2020 Oct; 30(10):5738-5747. PubMed ID: 32367419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.